References
- Tsai H-M, Lian ECY. Antibodies to von-Willebrand fac-tor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585–1594.
- Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocy-topenic purpura. N Engl J Med 1991; 325: 393–397.
- Shumak KH, Rock GA, Nair RC and the Canadian Apheresis Group. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Ann Intern Med 1995; 122: 569–572.
- Moake JL, Rudy CK, Troll JH, et al. Therapy of chron-ic relapsing thrombotic thrombocytopenic purpura with pred-nisone and azathioprine. Am J Hematol 1985; 20: 73–79.
- Allan DS, Kovacs MJ, ClarK WF. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 2001; 86: 844–850.
- Itala M, Remes K. Excellent response of refractory life-threatening thrombotic thrombocytopenic purpura to cyclosporine treatment. Clin Lab Haematol 2004; 26: 65–67.
- Veltman GA, Brand A, Leeksma OC, ten Bosch GJ, van Krieken JH, Briet E. The role of splenectomy in the treat-ment of relapsing thrombotic thrombocytopenic purpura. Ann Hematol 1995; 70: 231–236.
- MUSSO M, Porretto F, Crescimanno A, et al. Successful treatment of resistant thrombotic thrombocytopenic purpu-ra/hemolytic uremic syndrome with autologous peripheral blood stem and progenitor (CD34+) cell transplantation. Bone Marrow Transplant 1999; 24: 207–209.
- Bandarenko N, Brecher ME. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apheresis 1998; 13: 133–141.
- Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab (Letter). Lancet 2000; 358: 1511–1513.
- Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2000; 98: 952–957.
- Levine TD, Pestronk A. IgM antibody-related poly-neu-ropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999; 52: 1701–1704.
- Tsai H-M, Schulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol 2003; 70: 183–185.
- Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V. Successful treatment of severe thrombotic thrombo-cytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 2002; 71: 105–108.
- Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocy-topenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003; 138: 105–108.
- Gutterman LA, Kloster B, Tsai H-M. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Molecules Dis 2002; 28: 385–391.